0000000000528318

AUTHOR

Javier Garde-noguera

showing 3 related works from this author

165P Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small c…

2021

Pulmonary and Respiratory MedicineOncologybusiness.industryImmune checkpoint inhibitorsmedicineCancer researchMyeloid-derived Suppressor CellOverall survivalNon small cellNeutrophil to lymphocyte ratioLung cancermedicine.diseasebusinessJournal of Thoracic Oncology
researchProduct

Molecular subtyping of colon cancer (CC) based on mutational status of RAS, BRAF, and DNA mismatch repair (MMR) proteins. Prognostic value.

2016

e15094Background: CC is a heterogeneuous disease with clinical, pathological and biological variability. Molecular classification could indentify prognostic subtypes. Methods: 105 patients with sta...

0301 basic medicineCancer Researchbusiness.industryColorectal cancerDiseasemedicine.diseaseSubtyping03 medical and health sciences030104 developmental biology0302 clinical medicineMolecular classificationOncology030220 oncology & carcinogenesisCancer researchMedicineMutational statusDNA mismatch repairbusinessPathologicalValue (mathematics)Journal of Clinical Oncology
researchProduct

Soluble biomarker signature to predict outcome of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD1/PDL1 monoclonal antibodies.

2019

e20685 Background: Immunotherapy with anti-PD1/PDL1 monoclonal antibodies has become the second line standard treatment for most patients diagnosed of advanced Non-Small-Cell lung cancer (NSCLC). The aim of this study is to assess the utility of circulating biomarkers such as sPDL1, sPDL2, sCD137, sIDO, sTIM3, sCD28, sCD27, sCTLA4, sHVEM, sLAG3, sCD80 and sGITR for predicting efficacy of immunotherapy with anti-PD1/PDL1 therapies. Methods: Blood samples were collected before treatment from 50 NSCLC patients who received anti PD1/PDL1 therapies (second line). Plasma biomarkers´ levels were measured by Multiplex bead-based assays. Continuous variables were categorized using the median as a c…

Cancer Researchmedicine.drug_classbusiness.industrymedicine.medical_treatmentStandard treatmentnon-small cell lung cancer (NSCLC)Immunotherapymedicine.diseaseMonoclonal antibodySecond lineOncologymedicineCancer researchBiomarker (medicine)Lung cancerAnti pd1businessJournal of Clinical Oncology
researchProduct